A patient with a history of scleroderma presents with worsening respiratory symptoms, persistent hypertension, and signs of potential pulmonary involvement. Which nursing intervention is most appropriate to prioritize in this scenario?

B) Initiate oxygen therapy to maintain adequate oxygen saturation levels.

A) Educate the patient on energy-conservation techniques to manage fatigue.

B) Initiate oxygen therapy to maintain adequate oxygen saturation levels.

C) Encourage increased fluid intake to manage hypertension.

D) Schedule a follow-up appointment for routine blood pressure monitoring.

A patient with scleroderma is experiencing worsening respiratory symptoms, including increased dyspnea and fatigue. Her vital signs show persistent hypertension and tachycardia, and physical examination reveals decreased breath sounds and fine crackles at the lung bases. Which of the following nursing interventions is most appropriate to address her current respiratory status?

C) Position the patient in a semi-Fowler's position to facilitate easier breathing.

A) Encourage the patient to increase her physical activity to improve lung capacity.

B) Educate the patient on the use of inhaled bronchodilators to alleviate her symptoms.

C) Position the patient in a semi-Fowler's position to facilitate easier breathing.

D) Advise the patient to avoid all physical activity to prevent further respiratory distress.

A patient with scleroderma-related pulmonary fibrosis and pulmonary arterial hypertension has been started on an endothelin receptor antagonist and nintedanib. Two weeks later, they present with peripheral edema and mild jugular venous distension. Given these new symptoms, what is the most appropriate nursing intervention to prioritize?

B) Educate the patient on the importance of daily weight monitoring to manage fluid status.

A) Increase the dose of the endothelin receptor antagonist to improve pulmonary pressures.

B) Educate the patient on the importance of daily weight monitoring to manage fluid status.

C) Discontinue nintedanib temporarily to evaluate its impact on heart failure symptoms.

D) Encourage the patient to increase fluid intake to support renal function.

A patient with scleroderma-related pulmonary fibrosis and newly developed right-sided heart failure presents with peripheral edema and mild jugular venous distension. Which nursing intervention is most appropriate to address the patient's fluid overload while considering her complex condition?

C) Administer prescribed diuretics and monitor urine output closely

A) Encourage increased oral fluid intake to maintain hydration

B) Elevate the patient's legs when sitting to promote venous return

C) Administer prescribed diuretics and monitor urine output closely

D) Advise the patient to limit physical activity to reduce cardiac workload

A patient with pulmonary fibrosis and volume overload has been started on low-dose furosemide. Which assessment finding would indicate a significant complication of diuretic therapy that requires immediate intervention?

B) Potassium level of 3.0 mEq/L

A) Blood pressure of 120/80 mmHg

B) Potassium level of 3.0 mEq/L

C) Heart rate of 88 beats per minute

D) Jugular venous pressure of 6 cm above the sternal angle

A patient with pulmonary fibrosis and fluid overload is initiated on low-dose furosemide therapy. Which assessment finding would indicate that the diuretic therapy is effective?

A) Decreased jugular venous pressure

C) Presence of bilateral basilar crackles

A patient with scleroderma is on diuretic therapy and presents with mild dizziness, fatigue, decreased peripheral edema, and persistent bilateral basilar crackles. Given these findings, what is the most appropriate nursing intervention to address the patient's current symptoms and laboratory results?

D) Monitor the patient closely for signs of hypokalemia while reducing the furosemide dose.

A) Increase the dose of furosemide to enhance fluid removal.

B) Administer potassium supplements to correct the low potassium level.

C) Encourage the patient to increase fluid intake to improve hydration.

D) Monitor the patient closely for signs of hypokalemia while reducing the furosemide dose.

A patient with scleroderma is undergoing diuretic therapy and has reported mild dizziness and fatigue. Lab results show a slight decrease in potassium levels. Which nursing intervention is most appropriate to address these findings?

B) Administer supplemental potassium as ordered to prevent hypokalemia

A) Increase the dose of furosemide to enhance diuretic effect

B) Administer supplemental potassium as ordered to prevent hypokalemia

C) Encourage the patient to increase fluid intake to alleviate dizziness

D) Discontinue diuretic therapy to prevent further electrolyte imbalance

A patient with scleroderma is experiencing persistent bilateral basilar crackles despite improvements in fluid management and stable vital signs. Which nursing intervention would be most appropriate to address the lung involvement in this patient?

D) Consult with a pulmonologist for potential pulmonary rehabilitation.

A) Encourage increased oral fluid intake to help mobilize secretions.

B) Position the patient in a high-Fowler's position to facilitate lung expansion.

C) Administer an additional dose of diuretics to further reduce lung fluid.

D) Consult with a pulmonologist for potential pulmonary rehabilitation.

A patient with scleroderma has shown improvement in peripheral edema and energy levels after an adjustment in her treatment plan but continues to have bilateral basilar crackles upon lung auscultation. Which nursing intervention should be prioritized to address this persistent pulmonary symptom?

B) Educate the patient about pulmonary rehabilitation exercises

A) Increase the dose of diuretics to further reduce fluid accumulation

B) Educate the patient about pulmonary rehabilitation exercises

C) Monitor liver enzyme levels to rule out medication hepatotoxicity

D) Encourage increased fluid intake to thin secretions

Scleroderma - Nursing Case Study

Pathophysiology

• Primary mechanism: Scleroderma is characterized by excessive collagen deposition due to fibroblast activation, leading to skin thickening and hardening. This process results from an autoimmune response where the body's immune system mistakenly attacks its own connective tissue.

• Secondary mechanism: Vascular abnormalities play a crucial role, with endothelial cell injury causing narrowing and obliteration of small blood vessels. This contributes to Raynaud's phenomenon and can lead to tissue ischemia and damage.

• Key complication: These mechanisms can lead to significant organ involvement, including pulmonary fibrosis or hypertension, which are major contributors to morbidity and mortality in scleroderma patients.

Patient Profile

Demographics:

45-year-old female, office administrator

History:

• Key past medical history: Diagnosed with scleroderma 3 years ago, hypertension, mild gastroesophageal reflux disease (GERD)

• Current medications: Amlodipine, Omeprazole, Methotrexate

• Allergies: Penicillin

Current Presentation:

• Chief complaint: Increasing difficulty with swallowing and joint stiffness

• Key symptoms: Raynaud's phenomenon, skin thickening on fingers, fatigue, shortness of breath on exertion

• Vital signs: Blood pressure 150/95 mmHg, heart rate 105 bpm, respiratory rate 22 breaths per minute, temperature 98.6°F

Section 1

Change in Patient Status:

In the weeks following her initial presentation, the patient begins experiencing worsening respiratory symptoms. She reports increased shortness of breath that now occurs even with minimal exertion, such as walking short distances or climbing a few stairs. Her fatigue has also become more pronounced, impacting her ability to perform daily activities and manage her responsibilities as an office administrator. During a follow-up visit, her vital signs reveal persistent hypertension with a blood pressure of 160/100 mmHg, a heart rate of 110 bpm, and a respiratory rate of 24 breaths per minute, indicating possible respiratory compromise.

A physical examination is conducted, revealing decreased breath sounds at the lung bases and fine crackles upon auscultation. These findings, coupled with her increasing dyspnea, suggest the progression of pulmonary involvement, potentially indicating pulmonary fibrosis or early signs of pulmonary arterial hypertension, both known complications of scleroderma. Given the potential severity of these complications, her healthcare team decides to perform further diagnostic testing, including pulmonary function tests and a high-resolution CT scan of the chest, to evaluate the extent of lung involvement and guide further management.

This change in status requires the healthcare team to reassess her treatment plan, considering the need for more aggressive management of her pulmonary symptoms. This may involve adjustments to her current medications, such as optimizing her antihypertensive therapy with the addition of an endothelin receptor antagonist or phosphodiesterase-5 inhibitor, which are beneficial in managing pulmonary arterial hypertension. It is critical to address these changes promptly to prevent further deterioration and preserve her quality of life. The team also emphasizes the importance of regular monitoring and patient education regarding the signs of worsening respiratory function, empowering her to seek timely medical attention if needed.

Section 2

Following the completion of the pulmonary function tests and high-resolution CT scan, the results reveal a significant reduction in the patient's diffusing capacity for carbon monoxide (DLCO), confirming the presence of pulmonary fibrosis. Additionally, the CT scan shows evidence of ground-glass opacities and reticular patterns in the lung bases, consistent with interstitial lung disease. These findings align with her clinical presentation of worsening dyspnea and exertional intolerance. The healthcare team recognizes that these changes signify a moderate progression of her scleroderma-related lung involvement, necessitating a more targeted therapeutic approach.

In response to these diagnostic results, the patient's treatment plan is adjusted to include an endothelin receptor antagonist to address the pulmonary arterial hypertension component, alongside her existing antihypertensive regimen. The team also initiates therapy with nintedanib, an antifibrotic agent, to slow the progression of pulmonary fibrosis. These interventions aim to improve her respiratory function and prevent further decline. The patient is educated about the importance of medication adherence and advised to monitor her symptoms closely, understanding the critical nature of reporting any new or worsening respiratory issues promptly.

Despite these adjustments, the patient presents two weeks later with new symptoms of peripheral edema and mild jugular venous distension, suggesting the development of right-sided heart failure secondary to increased pulmonary pressures. Her laboratory tests indicate elevated levels of brain natriuretic peptide (BNP), further supporting this diagnosis. The healthcare team plans to integrate diuretics into her treatment regimen to manage fluid overload while continuing to optimize her pulmonary and cardiac care. This new complication underscores the complexity of her condition and the need for ongoing, comprehensive management to address the interconnected nature of her scleroderma manifestations.

Section 3

As the healthcare team integrates diuretics into the patient's treatment plan to manage her fluid overload, they conduct a thorough assessment to evaluate the current state of her cardiovascular and pulmonary systems. Upon examination, her vital signs reveal a blood pressure of 130/85 mmHg, a heart rate of 92 beats per minute, and oxygen saturation at 92% on room air. Auscultation of the lungs reveals bilateral basilar crackles, consistent with her pulmonary fibrosis, while heart sounds demonstrate a pronounced S2, suggesting increased pulmonary vascular resistance. The presence of peripheral edema is noted, extending up to her mid-calf, and her jugular venous pressure is measured at 8 cm above the sternal angle, indicative of volume overload.

Laboratory results show a BNP level of 450 pg/mL, confirming the strain on the right side of the heart. Additional tests reveal stable renal function with a creatinine level of 1.1 mg/dL, allowing for the cautious use of diuretics. Electrolyte levels, including potassium and sodium, remain within normal limits, which is reassuring given her added medications. The patient is counseled on the potential side effects of diuretics, such as electrolyte imbalance and dehydration, and is instructed to report any symptoms such as dizziness, weakness, or muscle cramps.

In response to these findings, the healthcare team decides to initiate low-dose furosemide therapy, with plans for close monitoring of her fluid status and electrolyte balance. Follow-up assessments will focus on evaluating the effectiveness of the diuretic therapy, along with continued surveillance for any signs of worsening heart failure or pulmonary involvement. This strategic approach aims to stabilize her current condition, mitigate the risk of further complications, and improve her overall quality of life. As the patient navigates these challenges, the healthcare team remains vigilant, ready to adjust the treatment plan as needed to address the dynamic nature of her scleroderma-related complications.

Section 4

Several days into the implementation of the diuretic therapy, the healthcare team conducts a follow-up assessment to evaluate the patient's response. The patient reports a mild reduction in peripheral edema but also mentions experiencing occasional dizziness and fatigue. Her vital signs reveal a blood pressure of 125/80 mmHg, a heart rate of 88 beats per minute, and oxygen saturation has improved slightly to 94% on room air. However, auscultation of the lungs continues to reveal persistent bilateral basilar crackles, indicating ongoing pulmonary fibrosis and fluid retention challenges. The jugular venous pressure is slightly reduced to 6 cm above the sternal angle, suggesting a modest improvement in her fluid status.

New laboratory results show a decrease in BNP levels to 390 pg/mL, indicating a reduction in cardiac strain. Electrolyte monitoring reveals a slight decrease in potassium levels to 3.4 mmol/L, which is approaching the lower limit of normal, necessitating close observation to prevent hypokalemia. The patient's renal function remains stable, with a creatinine level of 1.0 mg/dL, supporting the continued use of diuretics. Additionally, the team notices a mild increase in liver enzymes, which could suggest early hepatic congestion or medication side effects, warranting further investigation.

In light of these findings, the healthcare team decides to adjust the patient's treatment plan by supplementing potassium to prevent further decline and considers introducing an aldosterone antagonist to provide additional diuretic and cardioprotective effects. The patient's dizziness is attributed to a possible mild over-diuresis, prompting a slight reduction in the furosemide dosage. This nuanced approach addresses the delicate balance of managing fluid overload while minimizing adverse effects, demonstrating the importance of ongoing clinical reasoning and adaptation in the care of patients with complex conditions like scleroderma. The team remains vigilant, ready to further tailor the treatment strategy as the patient's journey unfolds.

Section 5

Several days after the adjustment in the treatment plan, the healthcare team conducts another follow-up assessment to evaluate the patient's response to the revised interventions. The patient reports feeling less dizzy, and her energy levels have slightly improved. Upon physical examination, her peripheral edema is noticeably reduced, suggesting improved fluid management. Her vital signs are stable with a blood pressure of 120/78 mmHg, a heart rate of 82 beats per minute, and an oxygen saturation of 95% on room air, indicating a positive response to the therapeutic adjustments.

New laboratory results reveal that the patient's potassium levels have stabilized at 3.8 mmol/L, due to the potassium supplementation, effectively preventing hypokalemia. Serum aldosterone levels are slightly reduced, indicating the beneficial effect of the newly introduced aldosterone antagonist. Despite these improvements, liver enzymes remain mildly elevated, necessitating further monitoring and consideration of potential hepatotoxicity from medications or scleroderma-related hepatic involvement. Renal function continues to be stable with a creatinine level of 1.0 mg/dL, supporting the ongoing use of diuretics.

While the patient's fluid status and symptoms have improved, auscultation of the lungs still reveals persistent bilateral basilar crackles, highlighting the challenge of managing pulmonary fibrosis in scleroderma. This finding prompts the healthcare team to consider additional therapeutic strategies, such as pulmonary rehabilitation or consultation with a pulmonologist, to address the chronic lung involvement. The team recognizes the complexity of the patient's condition, emphasizing the need for vigilant monitoring and a multidisciplinary approach to optimize her quality of life and prevent further complications. As the patient's journey progresses, the focus remains on closely adapting the care plan to her evolving needs.